ArriVent BioPharma Inc. (AVBP)
AVBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AVBP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001868279 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $113.6M cash; operating cash flow -$38.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,723,074 (2026-11-05); 41,281,361 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $13.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $5.0M | -$40.3M | -$40.7M | $113.6M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$49.9M | -$39.6M | $154.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$43.3M | -$41.9M | $62.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$35.5M | -$30.7M | $45.5M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$35.0M | -$35.8M | $112.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$31.4M | -$26.1M | $112.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$64.4M | -$68.0M | $49.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$20.6M | -$16.2M | $74.3M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-11 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 162 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.6% |
| 1 month | -19.1% |
| 3 months | -56.6% |
| Year to date | -35.3% |
| 1 year | -33.9% |
| From 52-week high | -62.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GERN | Geron Corporation | $0.9419 | -2.60% | $606.8M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| ABUS | Arbutus Biopharma Corporation | $4.04 | -1.22% | $619.3M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier